Minor histocompatibility antigens represented in HLA-A*02:01 and their search strategies

Q4 Medicine

Oncogematologiya Pub Date : 2023-09-13 DOI:10.17650/1818-8346-2023-18-3-115-124

D. S. Romanyuk, A. M. Pilunov, G. A. Efimov, A. V. Bogolyubova, E. N. Parovichnikova

引用次数: 0

Abstract

Minor histocompatibility antigens (MiHAs) are polymorphic peptides on the cell surface derived from self-proteins that are capable to induce an immune response during allogeneic hematopoietic stem cells transplantation. Their presentation occurs in the context of the certain major histocompatibility complex (HLA – human leucocyte antigen) alleles. One of the most common HLA alleles is HLA-A*02:01. Accordingly, for a significant number of donors and recipients pairs, it is possible to use the MiHAs presented in the HLA-A*02:01 as a target for relapsed leukemia therapy. This review discusses the main known MiHAs presented in the context of HLA-A*02:01, their characteristics and approaches used for identification. The described approaches may be used to search for new MiHAs for immunotherapy.

查看原文本刊更多论文

HLA-A*02:01所代表的次要组织相容性抗原及其搜索策略

次要组织相容性抗原(MiHAs)是细胞表面由自身蛋白衍生的多态肽，能够在异基因造血干细胞移植过程中诱导免疫反应。它们的表现发生在某些主要组织相容性复合体(HLA -人类白细胞抗原)等位基因的背景下。HLA- a *02:01是最常见的HLA等位基因之一。因此，对于相当数量的供体和受体，可以使用HLA-A*02:01中提出的MiHAs作为复发性白血病治疗的靶点。本文综述了HLA-A*02:01中已知的主要miha、它们的特点和鉴定方法。所描述的方法可用于寻找用于免疫治疗的新的miha。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Oncogematologiya Medicine-Hematology

CiteScore

0.50

自引率

0.00%

发文量

审稿时长

10 weeks

期刊介绍： The main purpose of the Oncohematology journal is to publish up-to-date information on clinical, experimental and fundamental scientific research, diagnostics and treatment options, as well as other materials on all relevant issues in oncohematology. The journal’s objectives are to inform various specialists who provide advisory and therapeutic assistance to patients with oncohematological diseases about current advances, including the latest methods for the diagnosis and treatment of malignant blood diseases. The journal is an interdisciplinary scientific publication uniting doctors of various specialties ‒ hematologists, oncologists, surgeons, radiation therapists, intensive care specialist, pathologists, etc. ‒ to form an interdisciplinary therapy approach in order to improve the treatment efficacy of patients with hematological malignancies.